Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Synthesis and Preclinical Evaluation of Glycoconjugate Vaccines against Group B Streptococcus Types VI and VIII

Lawrence C. Paoletti, Julieanne Pinel, Kenneth D. Johnson, Barbara Reinap, Robin A. Ross and Dennis L. Kasper
The Journal of Infectious Diseases
Vol. 180, No. 3 (Sep., 1999), pp. 892-895
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30111108
Page Count: 4
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Synthesis and Preclinical Evaluation of Glycoconjugate Vaccines against Group B Streptococcus Types VI and VIII
Preview not available

Abstract

Group B Streptococcus (GBS) types VI and VIII are prevalent among serotypes isolated from pregnant women in Japan. Maternal vaccination with a safe and effective GBS vaccine has been proposed as a rational approach to prevent neonatal GBS disease. Because antibody specific for the capsular polysaccharide (CPS) antigens of GBS is protective, vaccines were developed with purified type VI and VIII CPS coupled to tetanus toxoid. In rabbits the newly synthesized conjugate vaccines elicited high-titered, type-specific antibody that was opsonically active in vitro. Moreover, litters born to mice actively vaccinated with the conjugate vaccines, in contrast to uncoupled CPS or saline, were protected against an ordinarily lethal challenge of GBS of homologous serotype. GBS types VI and VIII conjugate vaccines of the design presented may be important components of a multivalent GBS vaccine for use in regions where these serotypes predominate.

Page Thumbnails

  • Thumbnail: Page 
892
    892
  • Thumbnail: Page 
893
    893
  • Thumbnail: Page 
894
    894
  • Thumbnail: Page 
895
    895